Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Anti-IL-4 receptor alpha monoclonal antibodies
12 evidence topics · 8 sources
Dupilumab as add-on treatment after high-dose antihistamines: 2026 international guideline
“We suggest using dupilumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, urticaria‐specific long‐term safety data are lacking, but existent studies in various diseases reflect a generally favorable safety profile” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data shows efficacy regardless of low baseline IgE levels for dupilumab, which is different compared to omalizumab where very low IgE values are often a reason for insufficient response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved indication in chronic spontaneous urticaria, ages 2 years and older: dupilumab
Dosage in chronic spontaneous urticaria by age and body weight: dupilumab
| Age and body weight | Initial loading dose | Subsequent dosage |
|---|---|---|
| 2 to 5 years, 5 to less than 15 kg | Not applicable | “200 mg (one 200 mg injection) every 4 weeks (Q4W)” |
| 2 to 5 years, 15 to less than 30 kg | Not applicable | “300 mg (one 300 mg injection) every 4 weeks (Q4W)” |
| 6 to 17 years, 15 to less than 30 kg | “600 mg (two 300 mg injections)” | “300 mg every 4 weeks (Q4W)” |
| 6 to 17 years, 30 to less than 60 kg | “400 mg (two 200 mg injections)” | “200 mg every 2 weeks (Q2W)” |
| 6 to 17 years, 60 kg or more | “600 mg (two 300 mg injections)” | “300 mg every 2 weeks (Q2W)” |
CUPID Study A and Study C in anti-IgE-naive participants: Week 24 efficacy in the label
| Week 24 outcome | Study A dupilumab (N=68) | Study A placebo (N=68) | Study A difference or odds ratio (95% CI) | Study C dupilumab (N=73) | Study C placebo (N=75) | Study C difference or odds ratio (95% CI) |
|---|---|---|---|---|---|---|
| ISS7, LS mean change (SE) | “-10.44 (0.92)” | “-6.02 (0.94)” | “-4.42 (-6.84, -2.01)” | “-8.50 (1.39)” | “-6.13 (1.38)” | “-2.37 (-4.48, -0.27)” |
| UAS7, LS mean change (SE) | “-20.99 (1.77)” | “-11.95 (1.81)” | “-9.04 (-13.68, -4.40)” | “-15.61 (2.62)” | “-11.27 (2.61)” | “-4.34 (-8.31, -0.36)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “3.23 (1.43, 7.27)” | “29 (39.7)” | “17 (22.7)” | “3.05 (1.32, 7.02)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “3.09 (1.24, 7.69)” | “22 (30.1)” | “13 (17.3)” | “2.73 (1.15, 6.50)” |
CUPID Study B in anti-IgE inadequate responders or intolerant participants: primary endpoint not met
LIBERTY-CSU CUPID Study A and Study B: phase 3 publication
“In LIBERTY-CSU CUPID Study A, patients were omalizumab-naive (n = 138, aged ≥6 years). In Study B, patients were omalizumab-intolerant/incomplete responders (n = 108, aged ≥12 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In Study A, UAS7 and ISS7 improved with dupilumab versus placebo (difference -8.5 [95% CI, -13.2 to -3.9; P = .0003] and -4.2 [95% CI, -6.6 to -1.8; P = .0005]). In Study B, tested at α = 0.043 after interim analysis, UAS7 improved (difference -5.8 [95% CI, -11.4 to -0.3; P = .0390]), with a numerical trend in ISS7 (difference -2.9 [95% CI, -5.7 to -0.07; nominal P = .0449, not significant]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although the primary end point for Study B was not met, dupilumab effects were small in patients who were omalizumab-intolerant/incomplete responders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse reactions in pooled CUPID Studies A, B, and C and immunogenicity in CSU: dupilumab
| Pooled CUPID Study A, B, and C | Dupilumab 200 mg or 300 mg Q2W (N=195) | Placebo (N=197) |
|---|---|---|
| Injection site reactions, n (%) | “20 (10.3)” | “16 (8.1)” |
| CSU population and regimen | Positive anti-drug antibody | Persistent anti-drug antibody | Neutralizing antibody |
|---|---|---|---|
| Adults and 12 years or older, 200 mg Q2W or 300 mg Q2W through 24 weeks | “9/193 (5%)” | “1/193 (1%)” | “2/9 (22%)” |
Efficacy by baseline serum IgE level: dupilumab
“Dupilumab treatment improved ISS7, UAS7, and HSS7 over 12 and 24 weeks, regardless of baseline serum IgE level (interaction p ≥ 0.59 for all treatment by subgroup comparisons), with weak correlations ( r < 0.2) observed between IgE level changes and ISS7, UAS7, and HSS7 outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the current analysis, baseline total IgE had no predictive value as a dupilumab treatment response biomarker in CSU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dupilumab in a network meta-analysis of systemic treatments for the Joint Task Force guideline update
Dupilumab compared with omalizumab and remibrutinib: network meta-analysis of 15 studies
“This study aims to compare the relative efficacy of omalizumab, dupilumab, and remibrutinib in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequentist random-effects network meta-analysis were conducted in R.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Dupilumab provided sustained itch relief but delayed efficacy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison of omalizumab with dupilumab: analysis with Genentech involvement
“To overcome this limitation, we used matching-adjusted indirect comparison to assess the efficacy of omalizumab versus dupilumab in primary phase 3 trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial ( NCT04180488 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genentech Inc was involved in the study design, data analysis, and preparation of the report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote